Table 2.

Systemic and local therapies administered

Pertuzumab administration
After SRS	24 (12.4%)
Before SRS	37 (19.1%)
Concurrent	22 (11.3%)
Not administered	111 (57.2%)
Not available	1 (0.5%)
Lapatinib administration
After SRS	35 (18.0%)
Before SRS	28 (14.4%)
Concurrent	18 (9.3%)
Not administered	113 (58.2%)
Not available	1 (0.5%)
Trastuzumab administration
After SRS	53 (27.2%)
Before SRS	60 (30.8%)
Concurrent	53 (27.2%)
Not administered	29 (14.9%)
Emtasine trastuzumab administration
After SRS	18 (9.3%)
Before SRS	2 (1.0%)
Concurrent	6 (3.1%)
Not administered	168 (86.6%)
Not available	1 (0.5%)
Immunotherapy administration
After SRS	2 (1.1%)
Not administered	179 (98.9%)
Not available	14 (7.1%)
Chemotherapy administration
After SRS	67 (34.4%)
Before SRS	68 (34.9%)
Concurrent	34 (17.4%)
Not administered	26 (13.3%)
Additional radiation	88 (45.8%)
Time to additional radiation	9.4 (4.5,12.9)
Additional surgery	24 (12.4%)
Time to additional surgery	15.9 (5.8,21.8)